The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Official Title: An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib
Study ID: NCT01593254
Brief Summary: The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Local Institution - 0004, Anaheim, California, United States
Local Institution - 0006, Fontana, California, United States
University Of Southern California University Hospital, Los Angeles, California, United States
Local Institution - 0110, Roseville, California, United States
Local Institution - 0112, San Jose, California, United States
Local Institution - 0009, Vallejo, California, United States
Local Institution - 0078, Whittier, California, United States
Local Institution - 0089, Southington, Connecticut, United States
Northwestern University, Evanston, Illinois, United States
Carle Cancer Center, Urbana, Illinois, United States
Northern Indiana Cancer Research Consortium, Crown Point, Indiana, United States
Franciscan St. Francis Health, Indianapolis, Indiana, United States
University Of Iowa, Iowa City, Iowa, United States
Local Institution - 0010, Rochester, Minnesota, United States
Local Institution - 0002, Cincinnati, Ohio, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Local Institution - 0001, Nashville, Tennessee, United States
Michael E Debakey VAMC, Houston, Texas, United States
Institute of Oncology Hematology Biomedical Research, Laredo, Texas, United States
Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States
Local Institution - 0005, Milwaukee, Wisconsin, United States
Local Institution - 0093, La Plata, Buenos Aires, Argentina
Local Institution - 0080, Ramos Mejia, Buenos Aires, Argentina
Local Institution - 0049, San Miguel de Tucuman, Tucuman, Argentina
Local Institution - 0051, Buenos Aires, , Argentina
Local Institution - 0057, Buenos Aires, , Argentina
Local Institution - 0100, Corrientes, , Argentina
Local Institution - 0026, Innsbruck, Tyrol, Austria
Local Institution - 0022, Wels, Upper Austria, Austria
Local Institution, Fuerstenfeld, , Austria
Local Institution - 0043, Graz, , Austria
Local Institution - 0024, Linz, , Austria
Local Institution - 0023, Wien, , Austria
Local Institution - 0065, Brugge, , Belgium
Local Institution - 0099, Merksem, , Belgium
Local Institution, Yvoir, , Belgium
Local Institution - 0083, Goiania, Goias, Brazil
Local Institution, Curitiba, Parana, Brazil
Local Institution - 0063, Campinas, SAO Paulo, Brazil
Local Institution, Ribeirão Preto, SAO Paulo, Brazil
Local Institution - 0059, São Paulo, SAO Paulo, Brazil
Local Institution - 0062, Rio de Janeiro, , Brazil
Local Institution - 0058, Rio de Janeiro, , Brazil
Local Institution - 0111, Rio de Janeiro, , Brazil
Local Institution - 0020, Saint John, New Brunswick, Canada
Local Institution - 0071, Beijing, Beijing, China
Local Institution - 0086, Beijing, Beijing, China
Local Institution - 0070, Fuzhou, Fujian, China
Local Institution - 0103, Shenzhen, Guandong, China
Local Institution - 0082, Guangzhou, Guangdong, China
Local Institution - 0074, Guangzhou, Guangdong, China
Local Institution - 0084, Haerbin, Heilongjiang, China
Local Institution - 0102, Wuhan, Hubei, China
Local Institution - 0073, Nanjing, Jiangsu, China
Local Institution - 0077, Suzhou, Jiangsu, China
Local Institution - 0094, Shenyang, Liaoning, China
Local Institution - 0088, Xian, Shan3xi, China
Local Institution - 0101, Jinan, Shandong, China
Local Institution - 0075, Chengdu, Sichuan, China
Local Institution - 0069, Tianjin, Tianjin, China
Local Institution - 0072, Hangzhou, , China
Local Institution - 0076, Shanghai, , China
Local Institution - 0096, Wuhan, , China
Local Institution - 0032, Brno, Czech Republic, Czechia
Local Institution, Hradec Kralove, , Czechia
Local Institution, Olomouc, , Czechia
Local Institution, Prague 10, , Czechia
Local Institution - 0067, Prague 2, , Czechia
Local Institution - 0045, Le Chesnay Cedex, , France
Local Institution - 0041, Lille cedex, , France
Local Institution, Nantes, , France
Local Institution, Pierre Bénite cedex, , France
Local Institution - 0038, Vandoeuvre-les-Nancy Cedex, , France
Local Institution, Budapest, , Hungary
Local Institution - 0104, Szeged, , Hungary
Local Institution - 0106, Brescia, Province Of Brescia, Italy
Local Institution, Bari, , Italy
Local Institution, Bologna, , Italy
Local Institution, Catania, , Italy
Local Institution - 0027, Firenze, , Italy
Local Institution - 0046, Monza, , Italy
Local Institution, Napoli, , Italy
Local Institution - 0025, Orbassano, , Italy
Local Institution - 0021, Roma, , Italy
Local Institution - 0033, Rome, , Italy
Local Institution - 0039, Seoul, , Korea, Republic of
Local Institution - 0050, Seoul, , Korea, Republic of
Local Institution - 0040, Seoul, , Korea, Republic of
Local Institution - 0048, Krakow, Malopolskie, Poland
Local Institution - 0047, Gdansk, , Poland
Local Institution - 0098, Katowice, , Poland
Local Institution - 0064, Warsaw, , Poland
Local Institution - 0017, A Couruna, , Spain
Local Institution - 0018, L'Hospitalet Del Llobregat, , Spain
Local Institution - 0015, Las Palmas de Gran Canaria, , Spain
Local Institution - 0012, Madrid, , Spain
Local Institution - 0013, Salamanca, , Spain
Local Institution - 0011, Toledo, , Spain
Local Institution - 0055, Muang, Chiang Mai, Thailand
Local Institution, Bangkok, , Thailand
Local Institution - 0052, Khon Kaen, , Thailand
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR